Afghanistan vs Sudan: Average cost of drugs for extensively drug-resistant tuberculosis
Afghanistan
2,000 constant 2022 US$
in 2024
Sudan
1,962 constant 2022 US$
in 2023
Afghanistan rank
24th
Sudan rank
26th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Afghanistan
- Sudan
How they compare
Afghanistan currently reports 2,000 constant 2022 US$ against 1,962 constant 2022 US$ in Sudan, a difference of 38 constant 2022 US$.
The two have swapped places 3 times across 6 shared years of data; in 2018 it was Sudan ahead.
Afghanistan ranks 24th and Sudan ranks 26th of 56 countries.
Across the 2 decades both report, Afghanistan averaged higher in 1 and Sudan in 1.
Head to head by decade
| Decade | Afghanistan | Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,350 constant 2022 US$ | 5,080 constant 2022 US$ | 2,730 constant 2022 US$ | Sudan |
| 2020s | 1,875 constant 2022 US$ | 1,672 constant 2022 US$ | 203.5 constant 2022 US$ | Afghanistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Afghanistan or Sudan?
- Afghanistan, at 2,000 constant 2022 US$ against 1,962 constant 2022 US$ in Sudan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Afghanistan and Sudan?
- 38 constant 2022 US$, with Afghanistan ahead.
- How many years of comparable data are there for Afghanistan and Sudan?
- 6 years are reported by both, from 2018 to 2023.
- How do Afghanistan and Sudan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Afghanistan ranks 24th and Sudan ranks 26th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.